Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

GLP-1/glucagon receptor co-agonism for treatment of obesity
Miguel A. Sánchez-Garrido, Sara J. Brandt, Christoffer Clemmensen, et al.
Diabetologia (2017) Vol. 60, Iss. 10, pp. 1851-1861
Open Access | Times Cited: 144

Showing 1-25 of 144 citing articles:

Incretin hormones: Their role in health and disease
Michael A. Nauck, Juris J. Meier
Diabetes Obesity and Metabolism (2018) Vol. 20, Iss. S1, pp. 5-21
Closed Access | Times Cited: 653
Glucagon-like peptide 1 in health and disease
Andreas Andersen, Asger Lund, Filip K. Knop, et al.
Nature Reviews Endocrinology (2018) Vol. 14, Iss. 7, pp. 390-403
Closed Access | Times Cited: 433
G protein-coupled receptors: structure- and function-based drug discovery
Dehua Yang, Qingtong Zhou, Viktorija Labroska, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 425
Emerging Targets in Type 2 Diabetes and Diabetic Complications
Sevgican Demir, Peter P. Nawroth, Stephan Herzig, et al.
Advanced Science (2021) Vol. 8, Iss. 18
Open Access | Times Cited: 318
Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
Marlene Chakhtoura, Rachelle Haber, Malak Ghezzawi, et al.
EClinicalMedicine (2023) Vol. 58, pp. 101882-101882
Open Access | Times Cited: 253
Signaling pathways in obesity: mechanisms and therapeutic interventions
Xue Wen, Bohan Zhang, Beiyi Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 242
Advances in therapeutic peptides targeting G protein-coupled receptors
Anthony P. Davenport, Conor C. G. Scully, Chris de Graaf, et al.
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 6, pp. 389-413
Open Access | Times Cited: 224
Drug Therapy in Obesity: A Review of Current and Emerging Treatments
David M. Williams, Asif Nawaz, Marc Evans
Diabetes Therapy (2020) Vol. 11, Iss. 6, pp. 1199-1216
Open Access | Times Cited: 166
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
Tamer Coşkun, Shweta Urva, William C. Roell, et al.
Cell Metabolism (2022) Vol. 34, Iss. 9, pp. 1234-1247.e9
Open Access | Times Cited: 158
Glucagon Receptor Signaling and Lipid Metabolism
Katrine D. Galsgaard, Jens Pedersen, Filip K. Knop, et al.
Frontiers in Physiology (2019) Vol. 10
Open Access | Times Cited: 153
Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review
Bertrand Cariou, Christopher D. Byrne, Rohit Loomba, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 5, pp. 1069-1083
Open Access | Times Cited: 143
GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
Riccardo Nevola, Raffaella Epifani, Simona Imbriani, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1703-1703
Open Access | Times Cited: 128
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Arun J. Sanyal, Pierre Bédossa, Mandy Fraessdorf, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 4, pp. 311-319
Open Access | Times Cited: 127
GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Jingyue Wang, Quanwei Wang, Xinyu Yang, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 121
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Patrick J. Knerr, Stephanie A. Mowery, Jonathan D. Douros, et al.
Molecular Metabolism (2022) Vol. 63, pp. 101533-101533
Open Access | Times Cited: 86
Obesity and the kidney: mechanistic links and therapeutic advances
Kevin Yau, Rachel Kuah, David Z.I. Cherney, et al.
Nature Reviews Endocrinology (2024) Vol. 20, Iss. 6, pp. 321-335
Closed Access | Times Cited: 31
A novel dual glucagon‐like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo‐controlled first‐in‐human and first‐in‐patient trials
J. Tillner, Maximilian Posch, Frank Wagner, et al.
Diabetes Obesity and Metabolism (2018) Vol. 21, Iss. 1, pp. 120-128
Open Access | Times Cited: 149
Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases
Christoffer Clemmensen, Brian Finan, Timo D. Müller, et al.
Nature Reviews Endocrinology (2018) Vol. 15, Iss. 2, pp. 90-104
Closed Access | Times Cited: 104
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease
F. Anthony Romero, Christopher T. Jones, Ying‐zi Xu, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 10, pp. 5031-5073
Closed Access | Times Cited: 81
Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy
Angeliki M. Angelidi, Matthew J. Belanger, Alexander Kokkinos, et al.
Endocrine Reviews (2021) Vol. 43, Iss. 3, pp. 507-557
Open Access | Times Cited: 81
Obesity–An Update on the Basic Pathophysiology and Review of Recent Therapeutic Advances
Erind Gjermeni, Anna Kirstein, Florentien Kolbig, et al.
Biomolecules (2021) Vol. 11, Iss. 10, pp. 1426-1426
Open Access | Times Cited: 65
Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity
David C. D. Hope, Matthew L. Vincent, Tricia Tan
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 60
Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease—Current Evidence
Emir Muzurović, Špela Volčanšek, Karin Zibar, et al.
Journal of Cardiovascular Pharmacology and Therapeutics (2022) Vol. 27
Open Access | Times Cited: 51
Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022
Harold Bays, Angela Fitch, Sandra Christensen, et al.
Obesity Pillars (2022) Vol. 2, pp. 100018-100018
Open Access | Times Cited: 47
The molecular pharmacology of glucagon agonists in diabetes and obesity
Aaron Novikoff, Timo D. Müller
Peptides (2023) Vol. 165, pp. 171003-171003
Open Access | Times Cited: 40
Page 1 - Next Page

Scroll to top